Jack Meehan
Stock Analyst at Barclays
(3.04)
# 1,269
Out of 5,134 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $276.67 | +4.82% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $123.87 | +0.91% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $321.43 | -10.40% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $9.05 | +264.64% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $116.51 | +178.95% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $14.47 | +31.31% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $205.49 | -51.82% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $88.62 | +103.11% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $4.50 | +122.22% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $164.44 | +0.95% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $43 | $75.13 | -42.76% | 9 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $158.53 | -2.86% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $264.93 | +62.31% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $267.57 | +60.70% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $23.13 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $38.12 | +25.92% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,353.24 | -49.75% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $68.83 | -56.41% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $501.59 | -40.19% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $0.88 | +4,471.43% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $276.67
Upside: +4.82%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $123.87
Upside: +0.91%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $321.43
Upside: -10.40%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $9.05
Upside: +264.64%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $116.51
Upside: +178.95%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $14.47
Upside: +31.31%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $205.49
Upside: -51.82%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $88.62
Upside: +103.11%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $4.50
Upside: +122.22%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $164.44
Upside: +0.95%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $75.13
Upside: -42.76%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $158.53
Upside: -2.86%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $264.93
Upside: +62.31%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $267.57
Upside: +60.70%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $23.13
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $38.12
Upside: +25.92%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,353.24
Upside: -49.75%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $68.83
Upside: -56.41%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $501.59
Upside: -40.19%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $0.88
Upside: +4,471.43%